Therapeuticsmd (TXMD)

Trade TXMD now with
9/20/2018 7:05:09 AM TherapeuticsMD Announces FDA Grants Annovera Marketing Exclusivity As A New Chemical Entity
9/13/2018 7:04:42 AM TherapeuticsMD Reports Commercial Availability Of Imvexxy 4 Mcg
8/1/2018 9:39:16 PM TherapeuticsMD Announces Pricing Of Public Offering And Registered Direct Offering For Aggregate Proceeds Of $85 Mln
7/31/2018 4:14:33 PM Knight Therapeutics Receives License To TX-004HR And TX-001HR In Canada And Israel From TherapeuticsMD
7/30/2018 6:18:07 AM TherapeuticsMD Q2 Net Loss $33.2 Mln Or $0.15/Shr Vs Loss $19.7 Mln Or $0.10/Shr Last Year
6/6/2018 7:04:15 AM TherapeuticsMD Announces Multiple Presentations At International Menopause Society’s 16th World Congress
5/30/2018 9:39:39 AM TherapeuticsMD Announces FDA Approval Of IMVEXXY Estradiol Vaginal Inserts For Dyspareunia Treatment
5/30/2018 6:05:30 AM TherapeuticsMD Announces FDA Approval Of TX-004HR: IMVEXXY
4/11/2018 6:02:05 AM TherapeuticsMD Enters Into Label Negotiations For TX-004HR